Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer

Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity

(2013) Chudi O. Ndubaku et al.   JOURNAL OF MEDICINAL CHEMISTRY

Comparison and validation of genomic predictors for anticancer drug sensitivity

(2013) Simon Papillon-Cavanagh et al.   JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION

The Clinical Relevance of Cancer Cell Lines

(2013) J.-P. Gillet et al.   JNCI-Journal of the National Cancer Institute

Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition

(2013) Barbara Burtness et al.   LANCET ONCOLOGY

Evaluating cell lines as tumour models by comparison of genomic profiles

(2013) Silvia Domcke et al.   Nature Communications

Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers

(2013) V. W. Y. Lui et al.   Cancer Discovery

High Frequency of Activating PIK3CA Mutations in Human Papillomavirus–Positive Oropharyngeal CancerPIK3CA in HPV+ Oropharyngeal Squamous Cell Carcinoma

(2013) Anthony C. Nichols   JAMA Otolaryngology-Head & Neck Surgery

Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment

(2012) Irene Brana et al.   BMC Medicine

Tumor Genetic Testing for Patient Selection in Phase I Clinical Trials: The Case of PI3K Inhibitors

(2012) Dejan Juric et al.   JOURNAL OF CLINICAL ONCOLOGY

Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor

(2012) S. NYLANDER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Systematic identification of genomic markers of drug sensitivity in cancer cells

(2012) Mathew J. Garnett et al.   NATURE

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Overcoming resistance to EGFR inhibitor in head and neck cancer: A review of the literature

(2012) Guilherme Rabinowits et al.   ORAL ONCOLOGY

Assembly and Initial Characterization of a Panel of 85 Genomically Validated Cell Lines from Diverse Head and Neck Tumor Sites

(2011) M. Zhao et al.   CLINICAL CANCER RESEARCH

UM-SCC-104: A New human papillomavirus-16-positive cancer stem cell-containing head and neck squamous cell carcinoma cell line

(2011) Alice L. Tang et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Promoter Methylation in Head and Neck Squamous Cell Carcinoma Cell Lines Is Significantly Different than Methylation in Primary Tumors and Xenografts

(2011) Patrick T. Hennessey et al.   PLoS One

Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1

(2011) N. Agrawal et al.   SCIENCE

The Mutational Landscape of Head and Neck Squamous Cell Carcinoma

(2011) N. Stransky et al.   SCIENCE

Inhibition of the PI3K Pathway: Hope We Can Believe in?

(2010) M. S. van der Heijden et al.   CLINICAL CANCER RESEARCH

Designing a Randomized Clinical Trial to Evaluate Personalized Medicine: A New Approach Based on Risk Prediction

(2010) S. G. Baker et al.   JNCI-Journal of the National Cancer Institute

Lung Cancer Cell Lines as Tools for Biomedical Discovery and Research

(2010) Adi F. Gazdar et al.   JNCI-Journal of the National Cancer Institute

Mitogen-activated protein kinase phosphatase-1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor-tyrosine kinase

(2009) Kenji Takeuchi et al.   FEBS Journal

fdrtool: a versatile R package for estimating local and tail area-based false discovery rates

(2008) K. Strimmer   BIOINFORMATICS

A unified approach to false discovery rate estimation

(2008) Korbinian Strimmer   BMC BIOINFORMATICS

The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†

(2008) Adrian J. Folkes et al.   JOURNAL OF MEDICINAL CHEMISTRY

Head and neck cancer

(2008) Athanassios Argiris et al.   LANCET